The splenic marginal zone is a site of blood flow, and the specialized B cell population that inhabits this compartment has been linked to the capture and follicular delivery of blood-borne antigens. However, the mechanism of this antigen transport has remained unknown. Here we show that marginal zone B cells were not confined to the marginal zone but continuously shuttled between the marginal zone and follicular areas, such that many of the cells visited a follicle every few hours. Migration to the follicle required the chemokine receptor CXCR5, whereas return to the marginal zone was promoted by the sphingosine 1-phosphate receptors S1P 1 and S1P 3 . Treatment with an S1P 1 antagonist caused displacement of marginal zone B cells from the marginal zone. Marginal zone-follicle shuttling of marginal zone B cells provides an efficient mechanism for systemic antigen capture and delivery to follicular dendritic cells.
The spleen is a chief site for the induction of antibody responses to blood-borne antigens. Many B cells in the spleen are situated in follicles in the white pulp, where they migrate over the processes of follicular dendritic cells (FDCs) in search of antigen. FDCs are also a source of B lymphocyte chemoattractant (BLC; also called CXCL13), a chemokine that attracts B cells to follicles by engaging the receptor CXCR5 (ref. 1) . Marginal zone B cells constitute a second chief B cell population in the spleen and are so named because of their location in the marginal zone between the areas of white and red pulp 2, 3 . The marginal zone is separated from the white pulp by the marginal sinuses, sites where terminal arterioles open and release blood 4 . The outer borders of the sinuses are porous, and blood can pass through the marginal zone before reaching the red pulp and returning to the circulation through venous sinuses. These features ensure that cells situated in the marginal zone are readily exposed to blood-borne antigens 2, 3 . Marginal zone B cells have a unique surface phenotype, with high expression of the complement receptors CD21 (CR2) and CD35 (CR1) and the nonclassical major histocompatibility complex molecule CD1d 3 . In rodents, marginal zone B cells are restricted to the spleen and do not recirculate 2 .
The pathways by which blood-borne antigens are delivered to splenic follicles have been under investigation for more than 30 years [5] [6] [7] . Several studies have shown that marginal zone B cells rapidly capture complement-opsonized antigens such as Ficoll via CD21 and CD35 (refs. 5-7) . Treatment with lipopolysaccharide or pertussis toxin causes displacement of marginal zone B cells from the marginal zone; this finding has been correlated with an immediate deficit in the ability of injected antigens to become deposited on FDCs [8] [9] [10] . Such studies linked marginal zone B cells to antigen transport but did not exclude the alternative possibility that other lipopolysaccharide-or pertussis toxin-sensitive cell types are required. The uncertainty about the contribution of marginal zone B cells to antigen transport has been amplified by the inability to detect a decrease in marginal zone B cell numbers in the marginal zone after exposure to opsonized antigen 8, 10 .
Positioning of marginal zone B cells in the marginal zone depends on the sphingosine 1-phosphate (S1P) receptor S1P 1 (ref. 11) , encoded by endothelial differentiation gene 1 (Edg1). Marginal zone B cells that lack S1P 1 or have been exposed to the S1P 1 -modulating drug FTY720 fail to localize in the marginal zone and are instead found inside the follicles 11, 12 . S1P is abundant in blood and is thought to be present in much smaller amounts in the follicles and T zones of lymphoid tissues 13, 14 . However, some studies have questioned the view that the requirement for S1P 1 indicates direct involvement of S1P in cell positioning and have instead suggested that the role of this ligandreceptor pair in lymphocyte function may be developmental 15, 16 . Also complicating the picture are experiments with T cells showing that continual exposure to blood S1P causes downmodulation of S1P 1 (refs. 14,17) , making it unclear if marginal zone B cells could continually respond to plasma S1P in the marginal zone.
Here, using a small-molecule antagonist, we provide evidence that engagement of S1P 1 by ligand is continually required for the positioning of marginal zone B cells in the marginal zone. Using mice either treated with FTY720 or lacking S1P 1 in B cells, we show that such positioning was necessary for capture of blood-borne antigens and for their efficient deposition on FDCs. However, if these cells lacked CXCR5 and were not able to migrate into follicles, antigen was no longer transported to FDCs. Using an in vivo antibody-labeling procedure, we find that in the resting state, up to half of the marginal zone B cells were located in the follicle. By comparing the amount of antibody labeling after 5 and 20 min, we obtained evidence that marginal zone B cells constitutively shuttled between marginal zone and follicle even in the absence of immunization and independently of B cell receptor (BCR) specificity or complement receptor expression. Follicle-to-marginal zone shuttling was regulated by the balance of the abundance of CXCR5 and S1P 1 . Finally, we show that S1P 3 contributed to the efficient positioning of marginal zone B cells in the marginal zone.
RESULTS

S1P 1 antagonists displace marginal zone B cells
To test whether engagement of S1P 1 by ligand is a constitutive requirement for the positioning of marginal zone B cells, we treated mice with the S1P 1 antagonist VPC44116 (ref. 18) . We treated mice for 3 h with three doses of VPC44116 or equivalent volumes of carrier and then isolated tissues for histological sectioning or flow cytometry. T cells from the blood, spleen and lymph nodes of treated mice had upregulated S1P 1 , which established that sufficient antagonist was injected to reduce engagement of the receptor by the ligand (Fig. 1a) . The less-complete upregulation of S1P 1 on cells in blood than in lymphoid tissue most probably reflected incomplete antagonism of receptor engagement by the large amounts of S1P in blood 13 . Although the S1P 1 antibody preparation specifically stains wild-type but not S1P 1 -deficient T cells 19 , extensive effort to stain B cells was unsuccessful because of the high nonspecific background staining on this cell type (data not shown). Analysis of tissue sections from mice treated for 3 h with VPC44116 showed that marginal zone B cells had relocalized into the follicles (Fig. 1b) . These data suggest that localization of marginal zone B cells in the marginal zone is promoted by S1P signaling through S1P 1 in these cells.
Marginal zone positioning facilitates antigen capture
As an approach to test the importance of marginal zone positioning in the capture of blood-borne antigen, we pretreated mice with FTY720 to cause displacement of marginal zone B cells into follicles 11 , then injected the mice intravenously with 5 mg or 50 mg of trinitrophenol (TNP)-Ficoll and analyzed the mice after 30 min. In saline-treated control mice, marginal zone B cells bound much more TNP-Ficoll than did follicular B cells, and this binding was dependent on CD21-CD35 ( Fig. 2a and data not shown) , as expected 20 . In contrast, in mice pretreated with FTY720, minimal TNP-Ficoll bound to most marginal zone B cells, similar to the amounts on follicular B cells (Fig. 2a) . The inclusion of allelically 'marked' ex vivo control B cells established that there was minimal in vitro capture of TNP-Ficoll complexes in mice injected with 5 mg TNP-Ficoll; we used this amount in all subsequent experiments. To further test if the diminished binding of TNP-Ficoll to marginal zone B cells was due to the redistribution of cells into follicles rather than an indirect effect of FTY720, we tested the effect of FTY720 on Ficoll binding in CXCL13-deficient mice. In these mice, FTY720 treatment does not cause displacement of marginal zone B cells from the marginal zone 11 and it had a minimal effect on Ficoll binding (Fig. 2b) . Similarly, FTY720 did not affect the binding of TNP-Ficoll by circulating B cells in the blood (Fig. 2c) .
A concern with the use of FTY720 to study access to a blood-borne antigen is the known activity of FTY720 in reducing vascular permeability 21 . We therefore did further experiments with S1P 1 -deficient fetal liver chimeras. As expected 11 , most marginal zone B cells in S1P 1 -deficient mice failed to localize in the marginal zone but instead were present in follicles (data not shown). Similar to the results obtained with FTY720 treatment, at 30 min after intravenous injection of TNPFicoll, marginal zone B cells in S1P 1 -deficient mice had bound little TNP-Ficoll (Fig. 2d) . To confirm that the effect of S1P 1 deficiency was due to loss of S1P 1 in B cells, we did experiments with mice heterozygous for a loxP-flanked ('floxed') allele encoding S1P 1 (Edg1 flox/-mice) 22 that had been crossed with mice with sequence encoding Cre recombinase inserted into the Cd19 locus (Cd19-Cre mice) 23 . Quantitative PCR analysis of sorted cells indicated that the Cre-mediated ablation of Edg1 in marginal zone B cells was efficient, and immunohistochemical staining showed that the lodgment of marginal zone B cells in the marginal zone was diminished to an extent similar to the amount in Edg1 -/-fetal liver chimeras (data not shown). Again, the marginal zone B cells bound little TNP-Ficoll (Fig. 2e) . Immunohistochemical analysis of tissue sections showed substantial TNP-Ficoll overlapping the B cell distribution in the splenic marginal zone of control mice (Fig. 2f) . In S1P 1 -deficient mice, there was still accumulation of TNP-Ficoll at the marginal zone but in a more punctate pattern, perhaps reflecting association with marginal zone macrophages (Fig. 2f) . These observations collectively suggest that localization of marginal zone B cells in the marginal zone is essential for their ability to rapidly capture blood-borne antigen.
Transport of marginal zone B cells antigen to follicles
Within 3 h of intravenous injection, large amounts of Ficoll are found on splenic FDCs. To assess whether marginal zone B cells must be present in the marginal zone for this transport to occur, we assessed the extent of deposition of TNP-Ficoll in follicles of mice pretreated with FTY720 or S1P 1 -deficient fetal liver chimeras. Both FTY720 pretreatment and S1P 1 deficiency diminished but did not completely block the deposition of TNP-Ficoll on FDCs, relative to the deposition in controls (Fig. 3a,b) . TNP-Ficoll deposition was similarly diminished in Cd19-Cre Edg1 flox/-mice ( Fig. 3c) , which confirmed that B cell expression of S1P 1 is required for the efficient deposition of opsonized Ficoll on FDCs.
Although the experiments reported above supported the conclusion that marginal zone B cells must localize in the marginal zone to facilitate the transport of a blood-borne antigen to FDCs, it remained possible that they were involved solely in the capture of the bloodborne antigen rather than in its transport. To further assess this, we used a mixed-bone marrow chimera approach to generate mice in which follicles could develop normally but marginal zone B cells would be unable to migrate from the marginal zone into follicles. In mice lacking CD19, follicles form but marginal zone B cells fail to develop, whereas in CXCR5-deficient mice, B cells develop normally but are unable to migrate into follicles, and the B cell areas lack FDCs [24] [25] [26] . When we reconstituted mice with a mixture of CD19-deficient and CXCR5-deficient bone marrow and injected them with TNP-Ficoll, there was very effective antigen capture by CXCR5-deficient marginal zone B cells but little or no deposition of this antigen on FDCs (Fig. 3d) . There was normal Ficoll deposition in mixed-bone marrow chimeric mice containing CXCR5-wild-type B cells (Fig. 3d) . Staining with antibody to CD35 (anti-CD35) confirmed the presence of FDCs in both types of mixed-bone marrow chimeric mice (Fig. 3d) . These experiments collectively provide evidence that marginal zone B cells not only capture systemic antigens in the marginal zone but also migrate in a CXCR5-dependent way to follicles to facilitate antigen deposition on FDCs.
Folliclular shuttling of marginal zone B cells
Despite the efficiency of the TNP-Ficoll transport detected in wildtype mice, we did not find a change in the number of B cells in the marginal zone after TNP-Ficoll injection (Fig. 4a and data not shown (for earlier time points)). However, in CD1d-stained sections of control spleens, we repeatedly noted cells staining with the same intensity as marginal zone B cells located inside splenic follicles ( Fig. 4a and data not shown). These combined observations led us to consider the possibility that there was constitutive migration of marginal zone B cells into follicles occurring by a mechanism independent of antigen capture mediated by complement receptor CR1-CR2.
To examine that possibility further, we needed a more quantitative method of assessing the number of B cells present in the marginal zone. As this compartment is rapidly exposed to blood-borne antigen, we sought to determine whether an antibody pulse-labeling procedure developed to label cells in the vascular compartment (J. Pereira and J.G.C., unpublished observations) could be applied and tested whether brief in vivo exposure to anti-CD21 would selectively label marginal zone B cells among splenic B cells. Flow cytometry of spleen cells from mice that had been treated for 5 min with phycoerythrinconjugated anti-CD21 showed strong staining on a fraction of the marginal zone B cells (Fig. 4b) . Microscopy showed intense staining on B cells in the marginal zone (Fig. 4c) . Notably, flow cytometry showed that the staining of marginal zone B cells was bimodal, with only about 50% of the cells becoming brightly labeled (Fig. 4b) . We speculated that the poorly labeled cells corresponded to cells that had been shielded from the injected antibody because they were present in follicles during the 5 min of treatment. Like lymph nodes, the white pulp cords of spleen are surrounded by stromal cells and associated extracellular matrix that together form a barrier restricting the free diffusion of molecules that are the size of antibodies [27] [28] [29] . Staining of follicular B cells was less than staining of marginal zone B cells, as expected, although there was a tendency for some of the cells to show positive staining (Fig. 4b) , consistent with the presence of recirculating follicular B cells in the splenic marginal zone and red pulp 30 . To test whether follicular localization shielded marginal zone B cells from exposure to the injected antibody, we treated S1P 1 -deficient mice with phycoerythrin-anti-CD21. In these mice, most marginal zone B cells were poorly stained 5 min after antibody injection (Fig. 4d,e) . A similarly small fraction of cells became labeled with phycoerythrin-anti-CD21 in mice that had been pretreated for 3 h with FTY720 (Fig. 4e) . We then injected CXCR5-deficient mice with phycoerythrin-anti-CD21 and found that all the marginal zone B cells became labeled within 5 min (Fig. 4f) . The intensity of staining on these cells was less than that of the brightly stained subset in wild-type controls, perhaps because there are many more B cells in the marginal zones of mice deficient in the CXCL13-CXCR5 axis than in control mice 26 . To address the concern that white pulp organization is disturbed in CXCR5-deficient mice, we also treated bone marrow chimeras that had been reconstituted with a mixture of CXCR5-deficient and S1P 1 -deficient bone marrow. These mice have well developed lymphoid follicles, but the CXCR5-deficient B cells are unable to access these areas. In these mice, all the CXCR5-deficient marginal zone B cells became rapidly labeled, whereas only few S1P 1 -deficient marginal zone B cells became labeled (Fig. 4g) , which was consistent with the conclusion that cells located in the marginal zone became heavily labeled, whereas cells present in the follicle were shielded from immediate exposure to the phycoerythrin-anti-CD21. We then sought to determine whether there was a change in the fraction of brightly labeled cells after 20 min and found at that time point, about 70% of marginal zone B cells were brightly labeled in wild-type mice (Fig. 4e,h ). After longer time periods, all marginal zone B cells became labeled with antibody, which was consistent with a study that examined labeling at 1 h after injection of biotin-anti-CD21 (ref. 29) . Notably, in Cd19-Cre Edg1 flox/-mice, most marginal zone B cells remained poorly labeled at 20 min and even at 40 min, which indicated that the enhanced labeling was not a result of free access of antibody to the follicle (Fig. 4e,i) . The brightly stained cells detected in these mice at 20 min seemed to correspond to the small number of cells residing in the marginal zone (Fig. 4c) . Reciprocally, in CXCR5-deficient mice, all the marginal zone B cells were brightly labeled, which was consistent with all of these cells being in the marginal zone and accessible to the antibody (Fig. 4c,j) .
The observations reported above are collectively consistent with the view that as many as 40% of the marginal zone B cells that were in the follicles of wild-type mice during the initial 5 min of labeling traveled back into the marginal zone during the next 15 min. If this were the case, we would anticipate that these cells would be replaced by cells labeled with phycoerythrin-anti-CD21 that migrated into the follicle from the marginal zone. Microscopy of splenic tissue sections obtained 20 min after antibody injection showed that in addition to the staining throughout the marginal zone, there was now also labeling of a population of B cells in the follicle (Fig. 4c) . In contrast, there were few cells stained brightly for CD21 in splenic sections from S1P 1 -deficient mice treated for 20 min (Fig. 4c) , which ruled out the possibility that the brightly staining cells arose because of diffusion of the antibody. To exclude the possibility that the brightly staining cells appearing in follicles after 20 min were all recirculating B cells, we also treated Cd19 -/-mice, which lack marginal zone B cells but have normal numbers of follicular B cells 23, 24 . This analysis indicated a lack of brightly stained cells (Fig. 4c) . In wild-type mice, we obtained similar findings in terms of marginal zone B cell labeling after injection of phycoerythrin-anti-CD21, phycoerythrinanti-B220, biotin-anti-CD35, fluorescein isothiocyanate-anti-CD21, phycoerythrin-anti-CD19 and phycoerythrin-anti-CD45.2 (data not shown), which indicated that the shuttling was not dependent on engagement of CR1-CR2 by anti-CD21 and that these results were not affected much by the nature of the antibody or the type of conjugation. The shuttling of marginal zone B cells did not depend on expression of CR1-CR2, as Cr2 -/-mice had similar labeling profiles at 5 and 20 min after injection of phycoerythrin-anti-CD45.2 (Fig. 4k) . In addition, shuttling of marginal zone B cells seemed to be independent of their BCR specificity. In mice with 'knock-in' of the immunoglobulin heavy chain, in which about half of the B cells are specific for hen egg lysozyme, marginal zone B cells were similarly distributed between the marginal zone and follicles whether they were specific for hen egg lysozyme or not (Fig. 4l) . As a further approach to assess the rapid migration of marginal zone B cells into the follicle, we sought to determine whether any marginal zone B cells that labeled with antibody during an initial pulse became protected from exposure to an antibody subsequently injected. Indeed, a fraction of the marginal zone B cells that had labeled with anti-CD35 during a 15-minute pulse were protected from labeling by anti-CD21 in the ensuing 5 min (Fig. 4m, top left quadrant, right  plot) . We noted the lower anti-CD35 staining on the protected (phycoerythrin-anti-CD21-negative) cells in repeated experiments, which might indicate that, after migration into follicles, there is rapid loss of some antibody to surrounding B cells or FDCs. In control mice treated with both antibodies simultaneously, the labeled marginal zone B cells bound both antibodies equally well, as expected (Fig. 4m, left plot) . These observations collectively indicate that many marginal zone B cells rapidly shuttle between marginal zone and follicle in a homeostatic way that is independent of engagement of complement receptor or BCR.
Activated C4 on marginal zone B cells
The antibody FDC-M2, widely used as an FDC marker, is now known to bind an activated form of complement C4 (ref. 31 ). In mice deficient in tumor necrosis factor, which have poorly developed follicles and lack FDCs, there is accumulation of cells staining with FDC-M2 in the marginal zone 32 . Similar findings have been reported for CXCR5-deficient mice 33 . We confirmed the marginal zone staining pattern of FDC-M2 in CXCR5-deficient mice (Fig. 5a) and noted similar staining in CXCL13-deficient mice (data not shown). Although it has been suggested that these cells may be mislocalized FDCs or FDC precursors 32, 33 , we speculated that in the absence of marginal zone-follicle shuttling, marginal zone B cells may be unable to 'off-load' complement-coated antigens on FDCs and might therefore accumulate C4-containing antigens over time. Indeed, by flow cytometry we found that the marginal zone B cells in CXCR5-deficient mice had much more active C4 on their surfaces (Fig. 5b,c) . Notably, CXCR5-deficient marginal zone B cells also had slightly more surface expression of CD21 (Fig. 5c) . However, the difference in FDC-M2 staining was at least threefold greater than the difference in CD21 expression, which suggested that the marginal zone B cells in unimmunized mice had the propensity to accumulate C4-containing immune complexes. Therefore, marginal zone B cell shuttling seems to have an homeostatic function in the deposition of complementopsonized antigens on FDCs. To test whether the balance of S1P 1 and CXCR5 activity was important in regulating the shuttling activity noted above, we analyzed by flow cytometry B cells from Edg1 -/-mice or mice heterozygous for CXCR5 deficiency (Fig. 6) . In Edg1 +/-mice treated for 5 or 20 min with phycoerythrin-anti-CD21, fewer cells were brightly labeled than in controls (Fig. 6a,c) , which indicated a shift in the balance in favor of follicular positioning. Although we have not been able to quantify S1P 1 surface protein on B cells because of high background staining, Edg1 +/-T cells have about half the amount of surface S1P 1 of wildtype T cells 17 . Reciprocally, a greater fraction of the cells was labeled with phycoerythrin-anti-CD21 within 5 min in mice hetrozygous for CXCR5 deficiency than in wild-type controls, and this was also true at 20 min (Fig. 6b,c) , which indicated that the 50% less CXCR5 in the heterozygous mice led to a shift in the balance of responsiveness in favor of S1P signaling and positioning in the marginal zone. These observations show a delicate balance of signaling by S1P 1 and CXCR5 and provide support for a model in which the principal function of each receptor in marginal zone B cells is to attract the cells to or retain the cells in the reciprocal compartments.
S1P 3 is required for positioning of marginal zone B cells
Although S1P 1 deficiency and FTY720 treatment led to considerable depletion of marginal zone B cells from the marginal zone and their accumulation in the follicle, the in vivo labeling approach with phycoerythrin-anti-CD21 showed that there was a residual population of B cells in the marginal zone that was detectable by flow cytometry and immunofluorescence analysis (Fig. 4c,d) .
Published work has shown that S1P 3, encoded by endothelial differentiation gene 3 (Edg3), is abundant in marginal zone B cells and supports strong S1P chemotactic responsiveness in vitro 11 , although the distribution of marginal zone B cells in S1P 3 -deficient mice seems to be little affected 11, 34 . Because the findings reported above indicated that many marginal zone B cells rapidly shuttle between follicle and marginal zone, it seemed likely that the chemotactic function of S1P 3 might be involved in the return of marginal zone B cells from the follicles to the marginal zone. For these studies, we used S1P 3 -deficient bone marrow chimeras to exclude the possible function of S1P 3 in stromal cells 34 . When we quantified the S1P 3 phycoerythrin-anti-CD21 or biotin-anti-CD35, the fraction was lower than that for control cells (Fig. 6d,e) . At 20 min, the extent of labeling of S1P 3 -deficient and control cells was similar (Fig. 6e) , perhaps reflecting less accurate quantification of cell distribution at this time point because of the increased staining of all B cells. These observations suggest that at homeostasis, a greater fraction of S1P 3 -deficient marginal zone B cells are located in the follicle than in the marginal zone relative to wild-type marginal zone B cells. Moreover, when we treated S1P 3 -deficient bone marrow chimeras with FTY720 and then assessed the marginal zone B cells remaining in the marginal zone, we found that more complete displacement of the cells had occurred (Fig. 6d,e) . Notably, treatment of S1P 3 -deficient mice with FTY720 did not fully block the shuttling of marginal zone B cells; in contrast to the minimal labeling with the injected antibody at 5 min, more marginal zone B cells became labeled at 20 min (Fig. 6d) . In summary, both S1P 1 and S1P 3 promote the positioning of marginal zone B cells in the marginal zone and an additional ligand-receptor system may exist that makes a contribution to marginal zone B cell positioning similar to that of S1P 3 .
DISCUSSION
Marginal zone B cells have long been thought to be a sessile cell population that localizes selectively in the splenic marginal zone. Our findings reported here have provided strong evidence that this is not the case and that instead the cells shuttle continuously back and forth between marginal zone and follicle. The propensity to shuttle into the follicle is promoted by CXCR5, whereas shuttling to the marginal zone is controlled mainly by S1P 1 and S1P 3 . The relative amount of these receptors is important in determining the propensity for the cells to dwell in one compartment versus the other. Our findings have indicated that shuttling of marginal zone B cells is important for the efficient capture and transport of complement-bound antigen from the blood to splenic FDCs. On the basis of our observations, together with the results of several other studies, we propose the following model to account for the marginal zone-follicle shuttling of marginal zone B cells. The abundance of S1P in blood and the blood-rich nature of the marginal zone make it likely that the marginal zone is an 'S1P-high' environment. Our demonstration that antagonism of S1P 1 ligand binding rapidly displaced marginal zone B cells is consistent with this conclusion. In contrast, the lymphoid regions of lymphoid organs are 'S1P-low' environments 13 . CXCL13 is abundant in follicles, and its transcript expression extends to the marginal sinus but not into the marginal zone 35, 36 . Marginal zone B cells have two-to threefold more expression of S1P 1 transcripts than do follicular B cells and have expression of CXCR5 transcripts similar to that of follicular B cells 11 (data not shown). Overexpression of S1P 1 in follicular B cells is sufficient to prevent them from migrating into splenic follicles in short-term transfer experiments 17 . We propose that after committing to a marginal zone fate and upregulating S1P 1 and S1P 3 , marginal zone B cells are attracted to the marginal zone, where they can adhere and resist the shear forces associated with local blood flow because of their high expression of the a L b 2 and a 4 b 1 integrins 37, 38 . However, we speculate that after a short period, they are exposed to a sufficient amount of S1P to downmodulate S1P 1 and no longer be retained efficiently in the marginal zone. Although reagents are not yet available to stain mouse B cells for S1P 1 , studies of T cells and transfected cell lines have shown that S1P 1 is highly sensitive to downmodulation after S1P exposure 13, [39] [40] [41] . After S1P 1 downmodulation, the response of marginal zone B cells to CXCL13 dominates and the cells migrate to the follicle. In the follicle, FDCs are thought to successfully compete for binding of opsonized antigens carried by the migrating marginal zone B cells because of their very high expression of CD21 and CD35. We suggest that after a short period of migration in this 'CXCL13-high' but 'S1P-low' environment, marginal zone B cells regain sufficient S1P 1 surface expression to respond again to marginal zone S1P and then migrate back to this compartment. When T cells migrate from blood into lymph nodes, they upregulate S1P 1 within 1.5 h (ref. 17) . The sensitive relationship between the surface abundance of S1P 1 and CXCR5 and propensity of marginal zone B cells to localize in the marginal zone or follicle suggests that even partial decreases or increases in receptor function might be sufficient to promote movement of the cell from one compartment to the other. Repeated cycles of this process would lead to constitutive shuttling of marginal zone B cells between marginal zone and follicle. Future work should further test this model by disrupting desensitization motifs in S1P 1 and CXCR5 and by developing approaches for imaging marginal zone B cell migration in real time in intact spleen.
The involvement of marginal zone B cells in the transport of opsonized antigens into follicles has long been under investigation [5] [6] [7] . Early electron microscopy studies identified rare examples of splenic (possibly marginal zone) B cells with labeled antigen at their uropod that may have been migrating in the direction of the follicle 42 . Correlative evidence that marginal zone B cells are needed for antigen transport was obtained by treatments that displace the cells and the demonstration that this diminished subsequent deposition of injected antigen on FDCs [8] [9] [10] . A study of anti-CD21 injection has also reported a correlation between initial labeling of marginal zone B cells and subsequent antibody appearance on FDCs 29 . However, those studies did not exclude the possibility of indirect effects of the treatments and did not establish how, after immune complex or antibody capture, the marginal zone B cells underwent repositioning into the follicle. Another experiment has shown that CD19-deficient mice are defective in the transport of immune complexes to splenic FDCs, consistent with involvement of marginal zone B cells but not excluding the possibility that these cells accomplish only the capture and other cells accomplish the transport 10 . Our work builds from those findings to directly demonstrate that marginal zone B cells must be located in the marginal zone to efficiently capture opsonized antigen and that their transport of the antigen may then be a 'default' feature of their shuttling activity rather than being induced by complement receptor engagement. Lipopolysaccharide exposure and BCR engagement promote the redistribution of marginal zone B cells from the marginal zone into the white pulp 2, 3 , and these stimuli cause transcriptional downregulation of S1P 1 and S1P 3 (ref. 11) . Our studies suggest that BCR engagement is not required for the shuttling of marginal zone B cells, but further work is needed to determine whether other receptor 'inputs' promote the shuttling activity.
Our finding that the fraction of marginal zone B cells labeled by injected anti-CD21 increased from about 50% to about 70% within 15 min suggested that as many as 40% of the marginal zone B cells that were in follicles during the first 5 min redistributed back to the marginal zone within 15 min (corresponding to about 20% of total marginal zone B cells). At this rate of flux, most marginal zone B cells would shuttle in and out of the follicle over a period of hours. Consistent with that, we found that in contrast to the heavy loading of the entire marginal zone B cell population with TNP-Ficoll 30 min after injection, the cells had all been mostly cleared of surface complexes by 2-3 h. This clearance seemed to depend on shuttling, as marginal zone B cells in CXCR5-and CXCL13-deficient mice failed to become cleared of surface labeling over the same time frame. Indeed, it would seem that constitutive shuttling contributes in an ongoing way to the removal of opsonized antigens from the surfaces of marginal zone B cells, as marginal zone B cells in CXCR5-and CXCL13-deficient mice had more activated C4 on their surfaces even in the absence of intentional immunization. Future studies should determine what fraction of these constitutive complexes contain autoantigens, as this might indicate that marginal zonefollicle shuttling and loading of FDCs with blood-borne antigen represent a mechanism promoting the self-tolerance of follicular B cells.
Although we found a substantial defect in antigen deposition on FDCs when marginal zone B cells were defective in shuttling to the marginal zone because of S1P 1 deficiency (or after FTY720 treatment), antigen deposition was not completely prevented. This was also true for FTY720-treated S1P 3 -deficient mice, the condition in which we noted the most severe defect in marginal zone B cell shuttling. We speculate that the residual transport and deposition of opsonized antigen on splenic FDCs was mediated by recirculating follicular B cells. Blood B cells were able to rapidly capture small amounts of injected Ficoll, and it has been shown that follicular B cells in lymph nodes capture and transport immune complexes to FDCs in a CD21-dependent way 43 .
The strong chemotactic activity of S1P 3 in marginal zone B cells made it unexpected that S1P 3 -deficient mice and bone marrow chimeras showed little evidence of impairment in B cell positioning in the marginal zone when examined nonquantitatively by immunohistochemistry 11, 34 . However, by quantitative flow cytometry, we have now been able to demonstrate a contribution of this receptor to the positioning of marginal zone B cells in the marginal zone. It remains puzzling that in chemotaxis assays, S1P 3 is more active than S1P 1 , yet in vivo, S1P 1 has greater involvement in promoting cell positioning in the marginal zone. One possible explanation for this discrepancy is that in vitro assays are poor in 'reporting' the in vivo 'pro-migratory' activity of S1P 1 , perhaps because of the high sensitivity of S1P 1 to downmodulation by its ligand. In preliminary experiments with transfected cells, we found that S1P 3 was more resistant to ligandmediated downmodulation than was S1P 1 (data not shown). In contrast to the activity of FTY720 in downmodulating and promoting the degradation of S1P 1 (refs. 40,41) , cells from mice injected with FTY720 retain S1P 3 function 11 . Thus, the more complete displacement of marginal zone B cells by FTY720 in S1P 3 -deficient mice than in wild-type mice is consistent with a failure of FTY720 to inactivate S1P 3 . It is notable that even S1P 3 -deficient mice retained small numbers of marginal zone B cells in the marginal zone after FTY720 treatment, which suggests that at least one further mechanism functions to promote localization of marginal zone B cells in this zone. Finally, it has been shown that shear forces are important for integrin activation by chemokines 38 . As the marginal zone is constantly flushed by blood, and integrins are vital for the lodgment of marginal zone B cells in the marginal zone 37 , it will be useful to study the involvement of shear forces in promoting the adhesion of marginal zone B cells as the cells shuttle into this zone.
METHODS
Mice, fetal livers and bone marrow chimeras. Wild-type C57BL/6 (B6) and congenic B6 CD45.1 mice 2-4 months old were from the National Cancer Institute. Edg1 +/-and Edg1 -/-fetal liver chimeras were generated as described 11 . Edg1 +/-mice 44 were crossed for 11 generations or more with B6 mice. Cd19-Cre mice 23 on a B6 background were crossed with Edg1 +/-mice. In the Cd19-Cre construct, insertion of the gene encoding Cre disrupts the Cd19 coding sequence, leading to homozygous Cd19 deficiency ('Cd19 Cre/Cre '; also called Cd19 -/-). Cd19 Cre/Cre Edg1 +/-mice were crossed with mice in which the Edg1 alleles were floxed (Edg1 flox/flox ) 22 . This resulted in Cd19-Cre Edg1 flox/+ or Cd19-Cre Edg1 flox/-mice in which the B cell lineage had either one or no functional Edg1 allele(s), respectively. For the generation of bone marrow chimeras, lethally irradiated B6 CD45.1 mice were reconstituted with bone marrow from Edg1 +/-fetal liver chimeras mixed at a ratio of 95:5 with bone marrow from CXCR5-deficient (Blr1 -/-) CD45.1 mice; bone marrow from Cd19 -/-mice mixed at a ratio of 90:10 with bone marrow from B6 CD45.1 or Blr1 -/-CD45.1 mice; bone marrow from Edg1 +/-B6 mice mixed at a ratio of 65:35 with bone marrow from B6 CD45.1 mice; bone marrow from Edg3 -/-(S1P 3 -deficient) mice mixed at a ratio of 50:50 with bone marrow from B6 CD45.1 mice; or with Edg3 -/-or CD45.1 bone marrow used alone. Cr2 -/-mice 45 , Cxcl13 -/-mice 46 , Blr1 -/-mice 47 , Edg3 -/-mice 48 and VDJ9-k5 mice (with B cells specific for hen egg lysozyme) 49 have been described. Mice were housed in a specific pathogen-free environment in the Laboratory Animal Research Center at the University of California, San Francisco, and all animal procedures were approved by the Institutional Animal Care and Use Committee at the University of California, San Francisco.
Treatments and TNP-Ficoll injection. For VPC44116 treatment 18 , the drug was first dissolved at a concentration of 20 mM in a mixture of dimethylsulfoxide and 1 N HCl (at ratio of 95:5) and was immediately diluted to a final concentration of 1 mM in aqueous solution containing 2% (wt/vol) 2-hydroxypropyl-b-cyclodextrin (Sigma). A control carrier solution was prepared in a similar way without VPC44116. Mice were injected intraperitoneally with 10 mg VPC44116 per kg body weight or the equivalent volume of carrier or saline solution. Mice were injected at 3, 2 and 1 h before being killed. For FTY720 pretreatment, mice were injected intraperitoneally at -3 h with 1 mg FTY720 per kg body weight or an equivalent volume of saline. For TNP-Ficoll deposition studies, mice were injected intravenously with various doses of TNP(89)-or TNP(65)-Ficoll (Biosearch Technologies) and were killed 30 min or 3 h later. Tissues were processed on ice to minimize further binding of the Ficoll in vitro.
In vivo labeling of B cells. For in vivo labeling of B cells, a method adapted from J. Pereira (unpublished data) was used. Mice were intravenously injected for various times with the following antibodies: 1 mg phycoerythrin-anti-CD21 (7G6, which recognizes both CD21 and CD35; BD Biosciences), 0.5 mg fluorescein isothiocyanate-anti-CD21 (7G6; BD Biosciences), 1 mg biotinanti-CD35 (8C12, which selectively recognizes CD35 only; BD Biosciences), 1 mg phycoerythrin-anti-CD19 (1D3; BD Biosciences), 5 mg phycoerythrinanti-CD1d (1B1; eBioscience), 2 mg phycoerythrin-anti-CD45.2 (104; eBioscience), or 1.5 mg phycoerythrin-anti-B220 (RA-3-6B2; Invitrogen, Caltag). Tissues were processed on ice to minimize further binding of the antibodies in vitro.
Flow cytometry and immunohistochemical analysis. A FACSCalibur or LSRII (Becton Dickinson) was used for flow cytometry. Staining with anti-S1P 1 has been described 17 . All other antibodies were from BD Biosciences. Marginal zone and follicular B cells were gated on CD19 + or B220 + cells. Marginal zone B cells were gated as CD23 lo CD21 hi or CD23 lo CD1d hi , and follicular B cells were gated as CD23 hi CD21 int or CD23 hi CD1d int . Because B cells may bind injected TNP-Ficoll or injected antibodies after processing of the tissue in vitro, tissues from syngeneic untreated mice were mixed with tissues from treated mice before further processing, and cells from these tissues were used as background controls. Immunohistochemistry and immunofluorescence analysis of spleen sections were done as described 11 .
Statistical analysis. Data were analyzed with a two-sample Student's t-test.
